BLIS Technologies Ltd (BLIS) is primarily involved in the development of healthcare products based on strains of bacteria that produce bacteriocin activity. The company offers a range of probiotic solutions for oral health, immunity, dental health, and skin health. It serves industries related to oral health, immunity, dental health, and skin health.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor incididunt ut labore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat.

BLIS’ R&D arm focus on improving its offerings and making newly developed technology profitable for the company. The company collaborates with leading universities and academics across New Zealand and globally on joint research projects, clinical trials, and academic partnerships. The R&D unit work with a diverse team of experts, including scientists, microbiologists, and formulators, to create innovative probiotic health solutions for the future. In FY2025, the company incurred expenses of NZD0.4 million on R&D, which as a percentage of revenue, stood at 3.1%.